Pathogenic role of interleukin-6 in the development of sepsis.: Part II:: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-α antibodies in a standardized murine contact burn model

被引:31
|
作者
Pallua, N [1 ]
Low, JFA [1 ]
von Heimburg, D [1 ]
机构
[1] Rhein Westfal TH Aachen, Univ Hosp, Dept Plast Surg & Hand Surg, Burn Ctr, D-52057 Aachen, Germany
关键词
interleukin-6; cytokines; cytokine antagonism; burn; sepsis; systemic inflammation; endotoxin;
D O I
10.1097/01.CCM.0000065725.80882.BD
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: The in vivo effects of anti-interleukin-6 (anti-IL-6) and anti-interleukin-6-alpha receptor (anti-IL-6R) monoclonal antibodies on immune response and survival rate of a burn with subsequent infection were assessed. Subjects: Ten-week-old C 57 BL/6J mice received a standardized contact burn; 48 hrs later endotoxin (LPS) was injected intraperitoneally to induce systemic inflammation. Ten different groups were studied. Groups I-IV sustained a burn and/or a LPS-stimulus but did not receive any anti-cytokines and served as controls. Treatment groups V-X sustained the same injuries but also received anti-IL-6 and anti-IL-6R intravenously either before or after the LPS stimulus. In a further part of the study, a lethal dose of LPS was injected (LPS-LD100 group) followed by an injection of anti-IL-6 antibody and/or anti-IL-6R antibody. Measurements: Serum concentrations of IL-6, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, and white blood cell and platelet counts were determined, and the survival rate over a 2-wk period was assessed. Results: Treatment with anti-IL-6 slightly decreased the inflammatory response when it was given before or after LIPS application. The inflammatory response was not decreased after treatment with anti-IL-6R. In the groups that received a combination of anti-IL-6 and anti-IL-6R, there was a significant reduction of the inflammatory response. This was more pronounced when the anti-cytokines were applied after LPS application. A significant reduction in mortality could be shown with both antibodies in the treatment groups and the groups that had received a lethal dose of LPS (LPS-LD100 group). Conclusions: IL-6 has a low inflammatory potential, and IL-6R has no inflammatory potential by itself. In contrast, the IL-6/IL-6R complexes have a higher inflammatory potential. Mortality could be reduced by each antibody alone as well as by the combination, supporting the hypothesis that the inflammatory and lethal potentials of IL-6 are not identical. The study suggests that the use of antibodies against IL-6 or IL-6R is effective in the prevention of systemic inflammation in a murine burn model.
引用
收藏
页码:1495 / 1501
页数:7
相关论文
共 50 条
  • [1] Pathogenic role of interleukin-6 in the development of sepsis. Part I: Study in a standardized contact burn murine model
    Pallua, N
    von Heimburg, D
    CRITICAL CARE MEDICINE, 2003, 31 (05) : 1490 - 1494
  • [2] PHARMACOKINETICS OF INTERLEUKIN-6 DURING THERAPY WITH ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODIES - ENHANCED CLEARANCE OF INTERLEUKIN-6 BY A COMBINATION OF 3 ANTI-INTERLEUKIN-6 ANTIBODIES
    MONTEROJULIAN, FA
    GAUTHEROT, E
    WIJDENES, J
    KLEIN, B
    BRAILLY, H
    JOURNAL OF INTERFERON RESEARCH, 1994, 14 (05): : 301 - 302
  • [3] ANTI-INTERLEUKIN-6 AND SOLUBLE INTERLEUKIN-6 RECEPTOR IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    EVANS, M
    ABDOU, NI
    LUPUS, 1994, 3 (03) : 161 - 166
  • [4] The role of interleukin-6 and interleukin-6/interleukin-6 receptor-α complex in the pathogenesis of multiple myeloma
    Barillé, S
    Bataille, R
    Amiot, M
    EUROPEAN CYTOKINE NETWORK, 2000, 11 (04) : 546 - 551
  • [5] Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
    Ridker, Paul M.
    Rane, Manas
    CIRCULATION RESEARCH, 2021, 128 (11) : 1728 - 1746
  • [6] The clinical role of interleukin-6 and interleukin-6 soluble receptor in human follicular fluids
    F. Kawasaki
    Y. Kawano
    Z. Kosay Hasan
    H. Narahara
    I. Miyakawa
    Clinical and Experimental Medicine, 2003, 3 : 27 - 31
  • [7] Role of serum interleukin-6 and soluble interleukin-6 receptor in postmenopausal bone loss
    Korzh, IV
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S97 - S97
  • [8] Comparison of Anti-Interleukin-6 and Anti-Interleukin-6 Receptor Antibodies Using In Vivo Functional Systems
    Shaw, Stevan
    Marshall, Diane
    Neale, Helen
    Kretsos, Kosmas
    Bourne, Tim
    Lawson, Alastair
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S708 - S709
  • [9] The clinical role of interleukin-6 and interleukin-6 soluble receptor in human follicular fluids
    Kawasaki, F
    Kawano, Y
    Hasan, ZK
    Narahara, H
    Miyakawa, I
    CLINICAL AND EXPERIMENTAL MEDICINE, 2003, 3 (01) : 27 - 31
  • [10] COMPARISON OF ANTI-INTERLEUKIN-6 AND ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODIES USING IN VIVO FUNCTIONAL SYSTEMS
    Shaw, S.
    Marshall, D.
    Neale, H.
    Kretsos, K.
    Bourne, T.
    Lawson, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 495 - 495